Dani Bach, formerly of Index Ventures, has joined the Switzerland-based private equity group, Aravis SA, as a managing partner. Dr Bach’s investment focus is protein therapeutics, neurodegeneration and medical devices. Prior to joining Index, he had a research position at the École Polytechnique Fédéral de Lausanne where he worked on the interactions between the human immunodeficiency virus and the human immune system.
Recent appointees also include Jacques Mizrahi, formerly of Roche, and Kadri Vunder, formerly of LSVenture GmbH.
Aravis announced the appointments on 9 January 2014.
Copyright 2014 Evernow Publishing Ltd.